Vyant Bio to Present at the LD Micro Main Event XV on

–To Discuss its Novel Drug Discovery Platform that is Accelerating the Process of Finding Cures for Neurogenerative Diseases

CHERRY HILL, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be presenting at the LD Micro Main Event XV on Wednesday, October 26, 2022, at 4:30 p.m. PT (7:30 p.m. ET) at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, will discuss key milestones and achievements on the scientific, business, and strategic front. The presentation slides will also be available in the Investors section of the Vyant Bio website.

Vyant management is also available for 1×1 meetings with interested parties at the conference all day on Wednesday, October 26^th. If interested, please request a meeting via the LD Micro conference website portal.

SUMMARY OF LD MICRO MAIN EVENT XV

“15 years ago, we set out to create an event that could benefit our entire industry. It wasn’t fast or easy, but we were honorable in our dealings and worked our tails off to ensure a wonderful time for everyone involved. Today, our community could not be larger, stronger, and more united as we go through these difficult and turbulent times together. The Main Event is about learning, connecting, and enjoying each other, and it is a hell of a lot more fun than sitting next to your computer,” stated Chris Lahiji, Founder of LD Micro.

…